ADAR1 Capital Management LLC Invests $3.32 Million in Invivyd, Inc. $IVVD

Key Points

• ADAR1 Capital Management acquired 3.81 million Invivyd shares worth approximately $3.32 million, representing a 1.29% stake. Institutional investors collectively own 70.36% of the company.
• Invivyd reported a quarterly loss of $0.14 per share, missing estimates by $0.03, while revenue of $14.29 million was slightly below expectations. Analysts expect a full-year loss of $0.51 per share.
• Analyst sentiment is mixed, with three Buy, two Hold, and one Sell rating, resulting in a consensus “Hold” rating and an $8.00 price target; the stock recently traded near $0.94.

ADAR1 Capital Management LLC acquired a new stake in Invivyd, Inc. (NASDAQ:IVVD - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,807,427 shares of the company's stock, valued at approximately $3,322,000. ADAR1 Capital Management LLC owned 1.29% of Invivyd as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp increased its stake in Invivyd by 9.0% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 106,900 shares of the company's stock valued at $139,000 after purchasing an additional 8,800 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Invivyd by 54.3% in the first quarter. Bank of New York Mellon Corp now owns 27,184 shares of the company's stock valued at $35,000 after buying an additional 9,568 shares in the last quarter. Courier Capital LLC acquired a new position in shares of Invivyd during the 4th quarter worth $25,000. Bronte Capital Management Pty Ltd. purchased a new stake in shares of Invivyd in the 4th quarter worth about $27,000. Finally, DRW Securities LLC acquired a new stake in Invivyd in the 4th quarter valued at about $27,000. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Stock Performance

IVVD opened at $0.94 on Wednesday. Invivyd, Inc. has a 1 year low of $0.53 and a 1 year high of $3.07. The firm has a 50 day moving average price of $0.78 and a 200 day moving average price of $1.20. The company has a market cap of $276.69 million, a PE ratio of -2.84 and a beta of 0.71.

Invivyd (NASDAQ:IVVD - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The business had revenue of $14.29 million during the quarter, compared to analysts' expectations of $14.40 million. On average, sell-side analysts predict that Invivyd, Inc. will post -0.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

IVVD has been the subject of several analyst reports. BTIG Research reissued a "buy" rating on shares of Invivyd in a research note on Tuesday, July 7th. Weiss Ratings downgraded shares of Invivyd from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday. HC Wainwright reaffirmed a "buy" rating on shares of Invivyd in a research note on Tuesday, August 18th. Finally, Wall Street Zen downgraded Invivyd from a "hold" rating to a "strong sell" rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Invivyd has a consensus rating of "Hold" and a consensus price target of $8.00.

Insiders Place Their Bets

In other Invivyd news, insider Jill Andersen sold 30,706 shares of Invivyd stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total transaction of $25,793.04. Following the sale, the insider directly owned 283,774 shares in the company, valued at $238,370.16. The trade was a 9.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 228,024 shares of company stock worth $176,540. 12.25% of the stock is owned by company insiders.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source